Read by QxMD icon Read

FISH testing in bladder cancer

Susanne Deininger, J Hennenlotter, S Rausch, K Docktor, E Neumann, I A da Costa, J Bedke, A Stenzl, T Todenhöfer
PURPOSE: The performance of urinary markers for detecting bladder cancer (BC) is influenced by various factors. The aim of the present study was to evaluate the influence of smoking habits on the performance of four commonly used urine markers. METHODS: Urine samples of 723 patients with suspected BC were analysed using urine cytology, fluorescence in situ hybridization (FISH), immunocytology (uCyt+ test), and quantitative nuclear matrix protein 22 (NMP22) immunoassay...
April 19, 2018: Journal of Cancer Research and Clinical Oncology
Bao Guan, Yicong Du, Xiaohong Su, Zhenpeng Cao, Yifan Li, Yonghao Zhan, Ding Peng, Gengyan Xiong, Dong Fang, Yi Ding, Shiming He, Yanqing Gong, Qun He, Xuesong Li, Liqun Zhou
Here, we evaluated the potential contribution of fluorescent in situ hybridization (FISH) as a prognostic risk factor of bladder recurrence and survival in patients with upper tract urothelial carcinoma (UTUC). A total of 159 UTUC patients were enrolled in this study from January 2012 to May 2016. The 159 voided urine samples before surgery were analyzed using the UroVysion® kit to detect the copy numbers of chromosomes 3, 7, 17 and 9p21 (p16). Patients were classified using an optimal cutoff value of chromosomes 3, 7, 17, and 9p21...
March 6, 2018: Oncotarget
Shizhen Zhang, Yan Wang, Jolanta Bondaruk, Tadeusz Majewski, Hui Yao, Sangkyou Lee, June Goo Lee, David Cogdell, Yair Lotan, Colin Dinney, Peng Wei, Keith Baggerly, Bogdan Czerniak
BACKGROUND: Bladder cancer is among the common human malignancies that show a heavy mutational load and copy number variations of numerous chromosomes, which makes them a target for diagnostic explorations. OBJECTIVE: We aimed to design a multicolor fluorescence in situ hybridization (FISH) test referred to as the quartet test for the detection of bladder cancer in urine. DESIGN, SETTING, AND PARTICIPANTS: We performed genome-wide copy number variation analysis on cohorts from the University of Texas MD Anderson Cancer Center (n=40) and The Cancer Genome Atlas (n=129), and identified the most frequently amplified chromosomal regions...
February 7, 2018: European Urology Focus
Esmee I M L Liem, Joyce Baard, Evelyne C C Cauberg, Mieke T J Bus, D Martijn de Bruin, M Pilar Laguna Pes, Jean J M C H de la Rosette, Theo M de Reijke
A significant number of patients with intermediate- or high-risk bladder cancer treated with intravesical Bacillus Calmette-Guérin (BCG) immunotherapy are non-responders to this treatment. Since we cannot predict in which patients BCG therapy will fail, markers for responders are needed. UroVysion(®) is a multitarget fluorescence in situ hybridization (FISH) test for bladder cancer detection. The aim of this study was to evaluate whether FISH can be used to early identify recurrence during treatment with BCG...
September 2, 2017: Medical Oncology
Vikram M Narayan, Oluwakayode Adejoro, Ian Schwartz, Matthew Ziegelmann, Sean Elliott, Badrinath R Konety
PURPOSE: Novel urinary tumor markers for bladder cancer may permit early detection and improved oncologic outcomes but data on use is limited. We sought to identify trends in the application of urinary markers and long-term outcomes of urinary tumor marker use in patients with bladder cancer. MATERIALS AND METHODS: Data from the SEER (Surveillance, Epidemiology and End Results)-Medicare database from 2001 to 2011 were used to identify a cohort of 64,450 patients with bladder cancer who underwent urinary marker testing with UroVysion® fluorescence in situ hybridization, or the NMP22® or BTA Stat® test...
January 2018: Journal of Urology
Tianhai Lin, Zhenhua Liu, Liangren Liu, Lu Yang, Ping Han, Peng Zhang, Qiang Wei
Urothelial carcinoma (UC) is the most common type of cancer of the bladder and upper urinary tract, and is characterized by a high risk of recurrence and progression. Urine fluorescence in situ hybridization (FISH) is a technique that detects genetic aberrations in exfoliated cells in the urine, with specific probes for chromosomes 3, 7 and 17 and the p16 gene. To evaluate the diagnostic value of FISH in UC, 119 patients from November 2010 to June 2012 with suspected UC were recruited into a prospective, cross-sectional study and were followed up for 12-30 months...
May 2017: Oncology Letters
Leonard G Gomella, Mark J Mann, Ryan C Cleary, Scott G Hubosky, Demetrius H Bagley, Adeep B Thumar, Peter A McCue, Costas D Lallas, Edouard J Trabulsi
INTRODUCTION: We evaluated the UroVysion (Abbott Molecular, IL, USA) fluorescence in situ hybridization (FISH) assay for the diagnosis of urothelial cancer in patients diagnosed with or suspected to have bladder, upper tract urothelial carcinoma (UTUC), and combined upper and lower tract urothelial carcinoma (BC). MATERIALS AND METHODS: A single institution retrospective analysis comparing sensitivity, specificity, positive predictive value, and negative predictive values for FISH and urinary cytology...
February 2017: Canadian Journal of Urology
Aaron Mobley, Shizhen Zhang, Jolanta Bondaruk, Yan Wang, Tadeusz Majewski, Nancy P Caraway, Li Huang, Einav Shoshan, Guermarie Velazquez-Torres, Giovanni Nitti, Sangkyou Lee, June Goo Lee, Enrique Fuentes-Mattei, Daniel Willis, Li Zhang, Charles C Guo, Hui Yao, Keith Baggerly, Yair Lotan, Seth P Lerner, Colin Dinney, David McConkey, Menashe Bar-Eli, Bogdan Czerniak
The effects of AURKA overexpression associated with poor clinical outcomes have been attributed to increased cell cycle progression and the development of genomic instability with aneuploidy. We used RNA interference to examine the effects of AURKA overexpression in human bladder cancer cells. Knockdown had minimal effects on cell proliferation but blocked tumor cell invasion. Whole genome mRNA expression profiling identified nicotinamide N-methyltransferase (NNMT) as a downstream target that was repressed by AURKA...
January 19, 2017: Scientific Reports
Ajay Gopalakrishna, Joseph J Fantony, Thomas A Longo, Richmond Owusu, Wen-Chi Foo, Rajesh Dash, Brian T Denton, Brant A Inman
PURPOSE: The aim of this study was to establish the criteria defining an anticipatory positive test for bladder cancer. METHODS: We reviewed all patients at our institution who underwent urine cytology or UroVysion fluorescence in situ hybridization (FISH) and cystoscopy from 2003 to 2012. Test performance and cancer anticipation was assessed using generalized linear mixed models, mixed-effects proportional hazards models, and cumulative incidence curves using tests performed within 30 days of each other as well as within a lag time of 1 year...
June 2017: Annals of Surgical Oncology
Johannes Mischinger, Lutz Philipp Guttenberg, Jörg Hennenlotter, Georgios Gakis, Stefan Aufderklamm, Steffen Rausch, Eva Neumann, Jens Bedke, Stefan Kruck, Christian Schwentner, Arnulf Stenzl, Tilman Todenhöfer
PURPOSE: Urine fluorescence in situ hybridization (FISH) has become a broadly used marker for noninvasive detection of bladder cancer (BC). However, it has been discussed whether the interpretation algorithm proposed by the manufacturer could be improved. Aim of the present study was to compare alternative evaluation strategies of FISH for detection of BC. METHODS: We included 1048 patients suspicious for BC, who underwent urine FISH examination before cystoscopy (diagnostic cohort)...
April 2017: Journal of Cancer Research and Clinical Oncology
Ajay Gopalakrishna, Thomas A Longo, Joseph J Fantony, Richmond Owusu, Wen-Chi Foo, Rajesh Dash, Brant A Inman
BACKGROUND: Spectrum effects refer to the phenomenon that test performance varies across subgroups of a population. When spectrum effects occur during diagnostic testing for cancer, difficult patient misdiagnoses can occur. Our objective was to evaluate the effect of test indication, age, gender, race, and smoking status on the performance characteristics of two commonly used diagnostic tests for bladder cancer, urine cytology and fluorescence in situ hybridization (FISH). METHODS: We assessed all subjects who underwent cystoscopy, cytology, and FISH at our institution from 2003 to 2012...
June 13, 2016: BMC Urology
Tian Zhang, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H Strickler, James L Abbruzzese, Michael R Harrison, David S Hsu, Patrick Healy, Jing Li, Cinthia Pi, Katherine M Prendergast, Carey Hobbs, Sarah Gemberling, Daniel J George, Herbert I Hurwitz, Mark Connelly, Mariano A Garcia-Blanco, Andrew J Armstrong
UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells (CTC) expressing c-MET using a ferromagnetic antibody. Immunofluorescence was used to characterize cells for c-MET, DAPI, and pan-CK, excluding CD45(+) leukocytes. The assay was validated using appropriate cell line controls spiked into peripheral blood collected from healthy volunteers (HV)...
June 2016: Molecular Cancer Research: MCR
Raquel D S Freitas, Kesiane M Costa, Natália F Nicoletti, Luiza W Kist, Maurício R Bogo, Maria M Campos
This study investigated the effects of the long-term dietary fish oil supplementation or the acute administration of the omega-3 fatty acid docosahexaenoic acid (DHA) in the mouse hemorrhagic cystitis (HC) induced by the anticancer drug cyclophosphamide (CYP). HC was induced in mice by a single CYP injection (300mg/kg ip). Animals received four different diets containing 10% and 20% of corn or fish oil, during 21days. Separated groups received DHA by ip (1μmol/kg) or intrathecal (i.t.; 10μg/site) routes, 1h or 15min before CYP...
January 2016: Journal of Nutritional Biochemistry
Emily G Barr Fritcher, Jesse S Voss, Shannon M Brankley, Michael B Campion, Sarah M Jenkins, Matthew E Keeney, Michael R Henry, Sarah M Kerr, Roongruedee Chaiteerakij, Ekaterina V Pestova, Amy C Clayton, Jun Zhang, Lewis R Roberts, Gregory J Gores, Kevin C Halling, Benjamin R Kipp
BACKGROUND & AIMS: Pancreatobiliary cancer is detected by fluorescence in situ hybridization (FISH) of pancreatobiliary brush samples with UroVysion probes, originally designed to detect bladder cancer. We designed a set of new probes to detect pancreatobiliary cancer and compared its performance with that of UroVysion and routine cytology analysis. METHODS: We tested a set of FISH probes on tumor tissues (cholangiocarcinoma or pancreatic carcinoma) and non-tumor tissues from 29 patients...
December 2015: Gastroenterology
Zhiming Ding, Hai-Wei Yang, Tian-Song Xia, Bo Wang, Qiang Ding
The RNA binding motif protein 38 (RBM38, also known as RNPC1) plays a pivotal role in regulating a wide range of biological processes, from cell proliferation and cell cycle arrest to cell myogenic differentiation. It was originally recognized as an oncogene, and was frequently found to be amplified in prostate, ovarian and colorectal cancer, chronic lymphocytic leukemia, colon carcinoma, esophageal cancer, dog lymphomas and breast cancer. In the present study, the complete RNPC1 gene was identified in a number of vertebrate genomes, suggesting that RNPC1 exists in all types of vertebrates, including fish, amphibians, birds and mammals...
August 2015: International Journal of Molecular Medicine
Ashish M Kamat, Daniel L Willis, Rian J Dickstein, Rooselvelt Anderson, Graciela Nogueras-González, Ruth L Katz, Xifeng Wu, H Barton Grossman, Colin P Dinney
OBJECTIVES: To present a molecular definition of bacille Calmette-Guérin (BCG) failure that incorporates fluorescence in situ hybridization (FISH) testing to predict BCG failure before it becomes clinically evident, which can be used to enhance trial designs for patients with non-muscle-invasive bladder cancer. PATIENTS AND METHODS: We used data from 143 patients who were followed prospectively for 2 years during intravesical BCG therapy, during which time FISH assays were collected and correlated to clinical outcomes...
May 2016: BJU International
Tilman Todenhöfer, Jörg Hennenlotter, Philipp Guttenberg, Sarah Mohrhardt, Ursula Kuehs, Michael Esser, Stefan Aufderklamm, Simone Bier, Niklas Harland, Steffen Rausch, Georgios Gakis, Arnulf Stenzl, Christian Schwentner
BACKGROUND: The role of urine markers in the surveillance of patients with non-muscle invasive bladder cancer (NMIBC) is discussed extensively. In case of negative cystoscopy the additional prognostic value of these markers has not been clearly defined yet. The present study is the first systematic approach to directly compare the ability of a urine marker panel to predict the risk of recurrence and progression in bladder cancer (BC) patients with no evidence of relapse during surveillance for NMIBC...
2015: BMC Cancer
Min Yan, Maria Schwaederle, David Arguello, Sherri Z Millis, Zoran Gatalica, Razelle Kurzrock
Human epidermal growth factor receptor 2 (HER2) amplification/overexpression is an effective therapeutic target in breast and gastric cancer. Although HER2 positivity has been reported in other malignancies, previous studies generally focused on one cancer type, making it challenging to compare HER2 positivity across studies/malignancies. Herein, we examined 37,992 patient samples for HER2 expression (+/- amplification) in a single laboratory. All 37,992 patients were tested by immunohistochemistry (IHC); 21,642 of them were also examined for HER2 amplification with either fluorescent in situ hybridization (FISH) (11,670 patients) or chromogenic in situ hybridization (CISH) (9,972 patients); 18,262 patients had tumors other than breast or gastric cancer...
March 2015: Cancer Metastasis Reviews
Tilman Todenhöfer, Jörg Hennenlotter, Michael Esser, Sarah Mohrhardt, Stefan Aufderklamm, Johannes Böttge, Steffen Rausch, Johannes Mischinger, Simone Bier, Georgios Gakis, Ursula Kuehs, Arnulf Stenzl, Christian Schwentner
BACKGROUND: The optimal use of urine markers in the surveillance of non-muscle-invasive bladder cancer (NMIBC) remains unclear. Aim of the present study was to investigate the combined and stepwise use of the four most broadly available urine markers to detect tumor recurrence in patients undergoing surveillance of NMIBC. PATIENTS AND METHODS: 483 patients with history of NMIBC were included. Cytology, UroVysion, fluorescence in situ hybridization (FISH), immunocytology (uCyt+), and NMP22 ELISA were performed before surveillance cystoscopy...
2014: Disease Markers
Casey Seideman, Daniel Canter, Philip Kim, Billy Cordon, Alon Weizer, Irma Oliva, Jianyu Rao, Brant A Inman, Michael Posch, Harry Herr, Yair Lotan
BACKGROUND: The significance of a positive UroVysion FISH assay is uncertain in patients with normal cystoscopy. This multicenter study evaluates the clinical significance of a positive FISH assay in patients with no visible tumor and excluding those with a positive cytology. METHODS: A multi-institutional, retrospective study of patients with a history of urothelial carcinoma of the bladder identified 664 patients with a FISH assay after excluding those with cystoscopic evidence of a tumor and/or positive cytology...
September 2015: World Journal of Urology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"